Hold and Kill” Therapeutic Fast Tracked for Metastatic Castration-Resistant Prostate Cancer

21 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
A new investigational therapy, nicknamed the “Hold and Kill” drug (HLD-0915), has just been granted Fast Track designation by the FDA for men with metastatic castration-resistant prostate cancer (mCRPC).

This innovative treatment is part of a new drug class called RIPTACs (regulated induced proximity targeting chimeras), designed to target and destroy prostate cancer cells by binding the androgen receptor with essential effector proteins. Early studies have shown tumor shrinkage and reduced PSA levels — offering new hope for patients facing advanced disease.

In this episode of UroNurse News, we break down:
✅ What “Hold and Kill” therapy is and how it works
✅ Why FDA’s Fast Track designation matters
✅ Current clinical trial details and patient outlook
✅ What this means for the future of prostate cancer treatment

???? Stay tuned for updates on this exciting breakthrough in oncology.

The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions.

#ProstateCancer #CancerResearch #FDAFastTrack #UroNurseNews #ProstateHealth #MedicalBreakthrough #CancerTreatment #MensHealth
Categoria
Oncology
Commenta per primo questo video.

Prossimo